GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » Altman Z-Score

NetraMark Holdings (XCNQ:AIAI) Altman Z-Score : -79.04 (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -77.5 is in distress zone. This implies bankruptcy possibility in the next two years.

NetraMark Holdings has a Altman Z-Score of -79.04, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for NetraMark Holdings's Altman Z-Score or its related term are showing as below:

XCNQ:AIAI' s Altman Z-Score Range Over the Past 10 Years
Min: -77.5   Med: -1.92   Max: 19.39
Current: -77.5

During the past 4 years, NetraMark Holdings's highest Altman Z-Score was 19.39. The lowest was -77.50. And the median was -1.92.


NetraMark Holdings Altman Z-Score Historical Data

The historical data trend for NetraMark Holdings's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings Altman Z-Score Chart

NetraMark Holdings Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Altman Z-Score
- - -0.83 -24.00

NetraMark Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.00 3.17 -24.00 -21.50 -73.04

Competitive Comparison of NetraMark Holdings's Altman Z-Score

For the Health Information Services subindustry, NetraMark Holdings's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NetraMark Holdings's Altman Z-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where NetraMark Holdings's Altman Z-Score falls into.



NetraMark Holdings Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

NetraMark Holdings's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.4577+1.4*-71.2619+3.3*-6.1897+0.6*66.6122+1.0*0.6392
=-79.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was C$0.49 Mil.
Total Current Assets was C$0.49 Mil.
Total Current Liabilities was C$0.26 Mil.
Retained Earnings was C$-34.56 Mil.
Pre-Tax Income was -0.716 + -0.853 + 0 + -1.433 = C$-3.00 Mil.
Interest Expense was 0 + 0 + 0 + 0 = C$0.00 Mil.
Revenue was 0.222 + 0 + 0 + 0.088 = C$0.31 Mil.
Market Cap (Today) was C$17.52 Mil.
Total Liabilities was C$0.26 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.485 - 0.263)/0.485
=0.4577

X2=Retained Earnings/Total Assets
=-34.562/0.485
=-71.2619

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-3.002 - 0)/0.485
=-6.1897

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=17.519/0.263
=66.6122

X5=Revenue/Total Assets
=0.31/0.485
=0.6392

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

NetraMark Holdings has a Altman Z-Score of -79.04 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


NetraMark Holdings  (XCNQ:AIAI) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


NetraMark Holdings Altman Z-Score Related Terms

Thank you for viewing the detailed overview of NetraMark Holdings's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


NetraMark Holdings (XCNQ:AIAI) Business Description

Traded in Other Exchanges
Address
1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.
Executives
Andrew Parks Director

NetraMark Holdings (XCNQ:AIAI) Headlines

No Headlines